VP-102 clinical trials
Also written VP-102.
How each study uses VP-102 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the VP-102 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 2018 | 3 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Verrica Pharmaceuticals Inc. (6)
Often tested with
Tested in the same studies.
TO-208 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 2 in phase 3
Studies that test VP-102, phase 3 first.
- Nov 2026Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)Phase 3 · Verrica Pharmaceuticals Inc.
- May 2027Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)Phase 3 · Verrica Pharmaceuticals Inc.
- Apr 2027Safety and Systemic Exposure of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris) (COVE-5)Phase 2 · Verrica Pharmaceuticals Inc.
Studies
Open first, then newest update. How each study uses VP-102 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Safety and Systemic Exposure of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris) (COVE-5)Not yet recruitingPhase 2Verrica Pharmaceuticals Inc.NCT07881952Written as VP-102
- Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)RecruitingPhase 3Verrica Pharmaceuticals Inc.NCT07637734Written as VP-102 (US) / TO-208 (Japan)
- Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)Active, not recruitingPhase 3Verrica Pharmaceuticals Inc.NCT07246590Written as VP-102
- Cantharidin and Occlusion in Verruca EpitheliumCompletedPhase 2Verrica Pharmaceuticals Inc.NCT03487549Written as VP-102 Cantharidin topical film forming solution
- Cantharidin Application in Molluscum Patients-1CompletedPhase 3Verrica Pharmaceuticals Inc.NCT03377790Written as VP-102 - Cantharidin, Topical Film Forming Solution
- Cantharidin Application in Molluscum PatientsCompletedPhase 3Verrica Pharmaceuticals Inc.NCT03377803Written as VP-102 - Cantharidin, Topical Film Forming Solution
What changed recently
From the registry's own updates since Oct 18, 2026.